Based on our findings and those previously published for metastatic staging, the adoption of a single preoperative PSMA PET scan may potentially replace the trio of preoperative conventional imaging tests currently ordered (MRI, CT abdomen and pelvis, and bone scan) in certain patients with intermediate-risk and high-risk prostate cancer. This evidence concerns the gene FOLH1 and Familial prostate cancer.